Patents by Inventor John R. Stephenson
John R. Stephenson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9926342Abstract: The present invention provides a recombinant protein comprising consecutive amino acids, the sequence of which is substantially identical to a sequence of amino acids present in a Rhodococcus equi virulence-associated protein and compositions containing fusion proteins of the invention. The present invention also provides uses of the compositions in the manufacture of hyperimmune plasma against Rhodococcus equi, in producing a hyperimmune plasma against Rhodococcus equi in protecting an animal against Rhodococcus equi and in protecting a newborn animal against Rhodococcus equi.Type: GrantFiled: March 13, 2014Date of Patent: March 27, 2018Assignee: SANTA CRUZ BIOTECHNOLOGY, INC.Inventor: John R. Stephenson
-
Publication number: 20150023983Abstract: The present invention provides a recombinant protein comprising consecutive amino acids, the sequence of which is substantially identical to a sequence of amino acids present in a Rhodococcus equi virulence-associated protein and compositions containing fusion proteins of the invention. The present invention also provides uses of the compositions in the manufacture of hyperimmune plasma against Rhodococcus equi, in producing a hyperimmune plasma against Rhodococcus equi in protecting an animal against Rhodococcus equi and in protecting a newborn animal against Rhodococcus equi.Type: ApplicationFiled: March 13, 2014Publication date: January 22, 2015Applicant: SANTA CRUZ BIOTECHNOLOGY, INC.Inventor: John R. Stephenson
-
Publication number: 20030166281Abstract: The present invention provides a method of transcriptionally modulating the expression of a gene-of-interest. The method comprises contacting a cell which is capable of expressing the gene with an amount of a molecule effective to transcriptionally modulate expression of the gene and thereby affect the level of the protein encoded by the gene which is expressed by the cell. Molecules useful in the practice of the invention are characterized as follows (a) do not naturally occur in the cell, (b) bind to DNA or RNA or bind to a protein through a domain of such protein which is not a ligand binding domain of a receptor which naturally occurs in the cell. Additionally, this invention provides a method for determining whether a molecule known to be a modulator of protein biosynthesis is capable of transcriptionally modulating expression of a gene-of-interest.Type: ApplicationFiled: April 16, 2002Publication date: September 4, 2003Applicant: OSI Pharmaceuticals, Inc.Inventors: J. Gordon Foulkes, Franz Leichtfried, Christian Pieler, John R. Stephenson, Robert Franco
-
Publication number: 20030138773Abstract: The present invention provides a method of transcriptionally modulating the expression of a gene of interest, the expression of which is associated with a defined physiological or pathological effect within a multicellular organism. The method comprises contacting a cell which is capable of expressing the gene with an amount of a molecule effective to transcriptionally modulate expression of the gene and thereby affect the level of the protein encoded by the gene which is expressed by the cell. Molecules useful in the practice of the invention are characterized as follows (a) do not naturally occur in the cell, (b) specifically transcriptionally modulate expression of the gene of interest, and (c) bind to DNA or RNA or bind to a protein through a domain of such protein which is not a ligand binding domain of a receptor which naturally occurs in the cell, the binding of a ligand to which ligand binding domain is normally associated with the defined physiological or pathological effect.Type: ApplicationFiled: March 25, 1998Publication date: July 24, 2003Inventors: J. GORDON FOULKES, ROBERT FRANCO, FRANZ LEITCHTFRIED, CHRISTIAN PIELER, JOHN R. STEPHENSON
-
Patent number: 6589733Abstract: The present invention provides a method of transcriptionally modulating the expression of a gene of interest, the expression of which is associated with a defined physiological or pathological effect within a multicellular organism. The method comprises contacting a cell which is capable of expressing the gene with an amount of a molecule effective to transcriptionally modulate expression of the gene and thereby affect the level of the protein encoded by the gene which is expressed by the cell. Molecules useful in the practice of the invention are characterized as follows (a) do not naturally occur in the cell, (b) specifically transcriptionally modulate expression of the gene of interest, and (c) bind to DNA or RNA or bind to a protein through a domain of such protein which is not a ligand binding domain of a receptor which naturally occurs in the cell, the binding of a ligand to which ligand binding domain is normally associated with the defined physiological or pathological effect.Type: GrantFiled: June 5, 1995Date of Patent: July 8, 2003Assignee: Osi Pharmaceuticals, Inc.Inventors: J. Gordon Foulkes, Robert Franco, Franz Leichtfried, Christian Pieler, John R. Stephenson
-
Patent number: 6586394Abstract: This invention is directed to a chromatographically recovered polypeptide having the N-terminal amino acid sequence Ala-Leu-Asp-Thr-Asn-Tyr-Cys-Phe-Arg-Asn-Leu-Glu-Clu-Asn-Cys-Cys-Val. This polypeptide is known as TGI, TGI-1 and TGI-2. It is also referred to as TGF-&bgr;3. The invention is also directed to a compositions which comprises the chromatographically recovered polypeptide. The invention also provides a pharmaceutical compositions to inhibit the growth of epithelial cells or heal a wound or treat a burn consisting of the chromatographically recovered polypeptide. The invention is also directed to methods which comprise administering to a subject an effective amount of the chromatographically recovered so as to thereby inhibit the growth of epithelial cells, or heal the wound or treat the burn.Type: GrantFiled: January 27, 1994Date of Patent: July 1, 2003Assignee: OSI Pharmaceuticals, Inc.Inventors: Kenneth K. Iwata, John R. Stephenson, Leslie I. Gold
-
Patent number: 6559123Abstract: This invention is directed to a method of treating a burn or healing a wound in a mammal by administering a chromatographically recovered polypeptide having the N-terminal amino acid sequence Ala-Leu-Asp-Thr-Asn-Tyr-Cys-Phe-Arg-Asn-Leu-Glu-Glu-Asn-Cys-Cys-Val. This polypeptide is known as TGI, TGI-1 and TGI-2. It is also referred to as TGF-&bgr;3. The invention is also directed to a compositions which comprises the chromatographically recovered polypeptide. The invention also provides a pharmaceutical compositions to inhibit the growth of epithelial cells or heal a wound or treat a burn consisting of the chromatographically recovered polypeptide.Type: GrantFiled: August 22, 1994Date of Patent: May 6, 2003Assignee: OSI Pharmaceuticals, Inc.Inventors: Kenneth K. Iwata, John R. Stephenson, Leslie I. Gold
-
Patent number: 6425769Abstract: The invention provides a recombinant nucleic acid vector comprising a nucleic acid encoding a polypeptide of 112 amino acids having the amino acid sequence shown in FIG. 29 beginning with alanine at position 1 and ending with serine at position 112. The sequence of FIG. 29 represents a member of the TGF-&bgr; family of tumor growth factors. The invention also provides a method for producing a protein which comprises culturing the host cell under conditions suitable to express the protein in the host cell and recovering the protein so produced.Type: GrantFiled: June 1, 1995Date of Patent: July 30, 2002Assignee: OSI Pharmaceuticals, Inc.Inventors: Kenneth K. Iwata, John R. Stephenson, Peter ten Dijke
-
Patent number: 6376175Abstract: The present invention provides a method of transcriptionally modulating the expression of a gene-of-interest. The method comprises contacting a cell which is capable of expressing the gene with an amount of a molecule effective to transcriptionally modulate expression of the gene and thereby affect the level of the protein encoded by the gene which is expressed by the cell. Molecules useful in the practice of the invention are characterized as follows (a) do not naturally occur in the cell, (b) bind to DNA or RNA or bind to a protein through a domain of such protein which is not a ligand binding domain of a receptor which naturally occurs in the cell. Additionally, this invention provides a method for determining whether a molecule known to be a modulator of protein biosynthesis is capable of transcriptionally modulating expression of a gene-of-interest.Type: GrantFiled: July 28, 1998Date of Patent: April 23, 2002Assignee: OSI Pharmaceuticals, Inc.Inventors: J. Gordon Foulkes, Franz Leichtfried, Christian Pieler, John R. Stephenson, Robert Franco
-
Patent number: 6203976Abstract: The present invention provides a method of transcriptionally modulating the expression of a gene encoding a protein of interest, the expression of which gene is associated with the production in cell culture of a protein encoded by the gene, which comprises contacting a cell, which is capable of expressing the gene, with an amount of a molecule effective to transcriptionally modulate expression of the gene and thereby affect the level of the protein encoded by the gene which is expressed by the cell in culture, which molecule (a) does not naturally occur in the cell and (b) directly transcriptionally modulates expression of the gene.Type: GrantFiled: June 7, 1994Date of Patent: March 20, 2001Assignee: OSI Pharmaceuticals, Inc.Inventors: J. Gordon Foulkes, Franz E. Leichtfried, Christian Pieler, John R. Stephenson
-
Patent number: 6165712Abstract: The present invention provides a method of transcriptionally modulating the expression of a gene encoding a protein of interest, the expression of which gene is associated with the production in cell culture of a protein encoded by the gene, which comprises contacting a cell, which is capable of expressing the gene, with an amount of a molecule effective to transcriptionally modulate expression of the gene and thereby affect the level of the protein encoded by the gene which is expressed by the cell in culture, which molecule (a) directly transcriptionally modulates expression of the gene.Type: GrantFiled: June 5, 1995Date of Patent: December 26, 2000Assignee: OSI Pharmaceuticals, Inc.Inventors: J. Gordon Foulkes, Franz E. Leichtfried, Christian Pieler, John R. Stephenson, Casey C. Case
-
Patent number: 6136779Abstract: The present invention provides a method of transcriptionally modulating the expression of a gene-of-interest. The method comprises contacting a cell which is capable of expressing the gene with an amount of a molecule effective to transcriptionally modulate expression of the gene and thereby affect the level of the protein encoded by the gene which is expressed by the cell. Molecules useful in the practice of the invention are characterized as follows (a) do not naturally occur in the cell, (b) bind to DNA or RNA or bind to a protein through a domain of such protein which is not a ligand binding domain of a receptor which naturally occurs in the cell. Additionally, this invention provides a method for determining whether a molecule known to be a modulator of protein biosynthesis is capable of transcriptionally modulating expression of a gene-of-interest.Type: GrantFiled: January 6, 1997Date of Patent: October 24, 2000Assignee: OSI Pharmaceuticals, Inc.Inventors: J. Gordon Foulkes, Franz Leichtfried, Christian Pieler, John R. Stephenson
-
Patent number: 6083709Abstract: The invention provides a method for diagnosing in a subject a neoplastic condition which comprises (a) obtaining from the subject a sample of a biological fluid; and (b) detecting the presence in the sample of a mutant p53 polypeptide encoded by an activated p53 oncogene, the presence of the mutant p53 polypeptide in the sample indicating that the subject has the neoplastic condition.Type: GrantFiled: November 23, 1993Date of Patent: July 4, 2000Assignee: OSI Pharmaceuticals, Inc.Inventors: Frederick H. Reynolds, Jr., Ron Zeheb, John R. Stephenson, John M. Sorvillo
-
Patent number: 5976793Abstract: The present invention provides a method of transcriptionally modulating the expression of a gene-of-interest. The method comprises contacting a cell which is capable of expressing the gene with an amount of a molecule effective to transcriptionally modulate expression of the gene and thereby affect the level of the protein encoded by the gene which is expressed by the cell. Molecules useful in the practice of the invention are characterized as follows (a) do not naturally occur in the cell, (b) bind to DNA or RNA or bind to a protein through a domain of such protein which is not a ligand binding domain of a receptor which naturally occurs in the cell. Additionally, this invention provides a method for determining whether a molecule known to be a modulator of protein biosynthesis is capable of transcriptionally modulating expression of a gene-of-interest.Type: GrantFiled: July 18, 1996Date of Patent: November 2, 1999Assignee: Oncogene Science, Inc.Inventors: J. Gordon Foulkes, Franz Leichtfried, Christian Pieler, John R. Stephenson
-
Patent number: 5863733Abstract: The present invention provides a method of transcriptionally modulating the expression of a gene-of-interest. The method comprises contacting a cell which is capable of expressing the gene with an amount of a molecule effective to transcriptionally modulate expression of the gene and thereby affect the level of the protein encoded by the gene which is expressed by the cell. Molecules useful in the practice of the invention are characterized as follows (a) do not naturally occur in the cell, (b) bind to DNA or RNA or bind to a protein through a domain of such protein which is not a ligand binding domain of a receptor which naturally occurs in the cell. Additionally, this invention provides a method for determining whether a molecule known to be a modulator of protein biosynthesis is capable of transcriptionally modulating expression of a gene-of-interest.Type: GrantFiled: January 6, 1997Date of Patent: January 26, 1999Assignee: Oncogene Science, Inc.Inventors: J. Gordon Foulkes, Franz Leichtfried, Christian Pieler, John R. Stephenson
-
Patent number: 5846720Abstract: The invention provided for a method of transcriptionally modulating the expression of a gene encoding a protein of interest associated with treatment of one or more symptoms of a cardiovascular disease. Further provided is a method of determining whether a molecule not previously known to be a modulator of protein biosynthesis is capable of directly and specifically transcriptionally modulating the expression of a gene encoding a protein of interest associated with treatment of one or more symptoms of a cardiovascular disease. Screening methods, including methods of essentially simultaneously screening molecules to determine whether the molecules are capable of directly and specifically transcriptionally modulating one or more genes encoding proteins of interest associated with treatment of one or more symptoms of a cardiovascular disease, are also provided.Type: GrantFiled: August 15, 1996Date of Patent: December 8, 1998Assignee: Oncogene Science, Inc.Inventors: J. Gordon Foulkes, Franz E. Liechtfried, Christian Pieler, John R. Stephenson, Casey C. Case
-
Patent number: 5776502Abstract: The present invention provides a method of transcriptionally modulating the expression of a gene of interest, the expression of which is associated with a defined physiological or pathological effect within a multicellular organism. The method comprises contacting a cell which is capable of expressing the gene with an amount of a molecule effective to transcriptionally modulate expression of the gene and thereby affect the level of the protein encoded by the gene which is expressed by the cell. Molecules useful in the practice of the invention are characterized as follows (a) do not naturally occur in the cell, (b) specifically transcriptionally modulate expression of the gene of interest, and (c) bind to DNA or RNA or bind to a protein through a domain of such protein which is not a ligand binding domain of a receptor which naturally occurs in the cell, the binding of a ligand to which ligand binding domain is normally associated with the defined physiological or pathological effect.Type: GrantFiled: June 2, 1995Date of Patent: July 7, 1998Assignee: Oncogene Science, Inc.Inventors: J. Gordon Foulkes, Robert Franco, Franz Leichtfried, Christian Pieler, John R. Stephenson
-
Patent number: 5665543Abstract: The present invention provides a method of transcriptionally modulating the expression of a gene-of-interest. The method comprises contacting a cell which is capable of expressing the gene with an amount of a molecule effective to transcriptionally modulate expression of the gene and thereby affect the level of the protein encoded by the gene which is expressed by the cell. Molecules useful in the practice of the invention are characterized as follows (a) do not naturally occur in the cell, (b) bind to DNA or RNA or bind to a protein through a domain of such protein which is not a ligand binding domain of a receptor which naturally occurs in the cell. Additionally, this invention provides a method for determining whether a molecule known to be a modulator of protein biosynthesis is capable of transcriptionally modulating expression of a gene-of-interest.Type: GrantFiled: June 28, 1994Date of Patent: September 9, 1997Assignee: Oncogene Science, Inc.Inventors: J. Gordon Foulkes, Franz Leichtfried, Christian Pieler, John R. Stephenson, Robert Franco
-
Patent number: 5580722Abstract: The invention provided for a method of directly and specifically transcriptionally modulating the expression of a gene encoding a protein of interest associated with treatment of one or more symptoms of a cardiovascular disease such as atherosclerosis, restenosis or hypertension.Further provided is a method of determining whether a molecule not previously known to be a modulator of protein biosynthesis is capable of directly and specifically transcriptionally modulating the expression of a gene encoding a protein of interest associated with treatment of one or more symptoms of a cardiovascular disease.Lastly, the invention provides a method of directly and specifically transcriptionally modulating in a human being the expression of a gene encoding a protein of interest associated with treatment of one or more symptoms of a cardiovascular disease, thus ameliorating the disease.Type: GrantFiled: February 7, 1992Date of Patent: December 3, 1996Assignee: Oncogene Science, Inc.Inventors: J. Gordon Foulkes, Franz E. Liechtfried, Christian Pieler, John R. Stephenson, Casey C. Case
-
Patent number: 4681840Abstract: A single-stranded deoxyribonucleic acid molecule having a length of less than about 25 kb comprises at least three distinct nucleotide sequences which are the sites for incorporation into a chromosome of a deoxyribonucleic acid molecule encoding a deleterious gene. Deoxyribonucleic acid probes have been prepared from such molecules and are useful as hybridization probes for detecting chromosomal deoxyribonucleic acid which has a deoxyribonucleic acid molecule encoding a deleterious gene, i.e. oncogene, incorporated therein.A single-stranded deoxyribonucleic acid molecule derived from human chromosome 22 which is about 5.8 kb in length contains sites for incorporation of a deoxyribonucleic acid molecule encoding the oncogene c-abl derived from human chromosome 9. Deoxyribonucleic acid probes have been prepared from this molecule and used to detect the abnormal Philadelphia chromosome and chronic myelocytic leukemia.Type: GrantFiled: January 18, 1984Date of Patent: July 21, 1987Assignee: The United States of America as represented by the Secretary of CommerceInventors: John R. Stephenson, John Groffen, Nora Heisterkamp